Analysts Offer Insights on Healthcare Companies: and Can-Fite BioPharma (CANF)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Can-Fite BioPharma (CANFResearch Report) with bullish sentiments.

Can-Fite BioPharma (CANF)

Dawson James analyst Jason Kolbert maintained a Buy rating on Can-Fite BioPharma on January 5 and set a price target of $7.00. The company’s shares closed last Tuesday at $1.09, close to its 52-week low of $0.94.

According to TipRanks.com, Kolbert is a 3-star analyst with an average return of 2.3% and a 39.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Can-Fite BioPharma with a $7.00 average price target, a 530.6% upside from current levels. In a report issued on January 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CANF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed